Estay Greene, PharmD, MBA

New ADA 2026 guidance expands CGM beyond insulin, boosting A1C, time-in-range and cutting costs—tips for patients, providers, payers.

Higher CGM use links to bigger A1c drops in type 2 diabetes, revealing how monitoring and meds like GLP-1s drive better control.

Frequent CGM use ties to bigger A1c drops in type 2 diabetes, even across GLP-1, SGLT2, and insulin regimens.

Learn how continuous glucose monitors fit school, work, and hospitals, reducing finger sticks, improving sleep, and clarifying alarm options.

See how 2026 ADA guidance broadens CGM use beyond insulin, urges payer coverage, and highlights kids, pregnancy, and older adults at risk.

See how continuous glucose monitors replace painful finger sticks, deliver real-time alerts, and help prevent dangerous highs and lows.

CGM delivers real-time glucose trends and alerts, enabling personalized diet changes, fewer fingersticks, and proactive care that can reduce medications, complications, and costs.

Discover ADA CGM updates, real-time glucose benefits, and the long-term savings from fewer complications and hospital stays.

Diabetes drives 25% of U.S. healthcare spending; see how CGM tech cuts finger sticks and shifts costs for patients and payers.